Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Handling insurance after the storm
Recommended
Homeowners insurance doesn't cover floods: How to protect your home in North Carolina
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
0.4707
-0.0488 (-9.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bluebird Bio
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
21
22
Next >
7 Nasdaq Stocks Down 59% Set to Soar at Least 141%
December 12, 2023
Wall Street always think companies are high-growth potential stocks but a little circumspection is required before buying
Via
InvestorPlace
4 Analysts Have This to Say About bluebird bio
December 12, 2023
Via
Benzinga
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 11, 2023
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the...
Via
Benzinga
What's Going On With Bluebird Bio Stock?
December 08, 2023
Bluebird Bio, Inc.
Via
Benzinga
2 Biotech Stocks That Could Soar in December
November 26, 2023
These two biotechs have important catalysts coming up in December.
Via
The Motley Fool
Is Bluebird Bio Stock a Buy?
November 04, 2023
This biotech looks cheap, but is it a value trap?
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
December 11, 2023
Via
Benzinga
What's Going On With Bluebird Bio Stock?
December 11, 2023
Bluebird Bio Inc (NASDAQ: BLUE) shares are trading higher Monday after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American...
Via
Benzinga
Cigna Calls Off Humana Merger, Joins Macy's, Snap And Other Big Stocks Moving Higher In Monday's Pre-Market Session
December 11, 2023
U.S. stock futures were mixed this morning, with the Dow Jones futures trading almost flat on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
December 11, 2023
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider.
Via
The Motley Fool
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
December 10, 2023
From
bluebird bio, Inc.
Via
Business Wire
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
December 09, 2023
From
bluebird bio, Inc.
Via
Business Wire
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
December 08, 2023
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y
Via
Benzinga
Exposures
Product Safety
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
December 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
December 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
Torrid Reports Upbeat Results, Joins MBIA, Virco Mfg. And Other Big Stocks Moving Higher On Friday
December 08, 2023
U.S. stocks traded mostly higher, with the Dow Jones index gaining more than 40 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
These 2 Stocks Could Be About to Soar: Are They Buys?
December 07, 2023
One thing is for certain -- both of these companies are innovators.
Via
The Motley Fool
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
November 29, 2023
As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks.
Via
InvestorPlace
Why FLJ Group Shares Are Trading Higher By Around 96%? Here Are Other Stocks Moving In Friday's Mid-Day Session
November 24, 2023
Shares of FLJ Group Limited (NASDAQ: FLJ) shares jumped during Friday’s session after the company announced it entered into a definitive agreement to acquire Alpha Mind Technology. FLJ Group shares...
Via
Benzinga
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
November 20, 2023
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?
Via
The Motley Fool
Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday
November 08, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Via
Benzinga
Why Bluebird Bio Stock Soared 7% Higher on Tuesday
November 07, 2023
The company posted some encouraging numbers and said it had sufficient resources to take care of financial obligations through the second quarter of 2024.
Via
The Motley Fool
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
November 07, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
November 02, 2023
From
bluebird bio, Inc.
Via
Business Wire
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.
Via
The Motley Fool
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
October 30, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
October 24, 2023
From
bluebird bio, Inc.
Via
Business Wire
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges
October 17, 2023
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches...
Via
Benzinga
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
October 17, 2023
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
21
22
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.